Filing Flows › Biodesix (BDSX) › Q2 2026 › vs Q1 2026
Biodesix (BDSX) Q2 2026 vs Q1 2026 (quarter over quarter)
Biodesix's revenue rose $1.3M (+5%) from $25.6M in Q1 2026 to $26.9M in Q2 2026. The biggest changes: Diagnostic Tests +$3.1M (+14%); Development Services −$1.8M (-54%).
Biodesix, Q2 2026: revenue $26.9M (+34% year over year), operating margin -20.1%, net loss $7.3M, operating cash flow −$1.6M. The chart draws each line against Q1 2026, the increases inside each band.
Every line
| Line | Q2 2026 | Q1 2026 | Change | % |
|---|---|---|---|---|
| Diagnostic Tests | $25.3M | $22.3M | $3.1M | +14% |
| Development Services | $1.5M | $3.3M | −$1.8M | -54% |
| Revenue | $26.9M | $25.6M | $1.3M | +5% |
| Net loss | $7.3M | $7.8M | −$520K | -7% |
| Costs & expenses | $34.1M | $33.3M | $786K | +2% |
| Operating costs | $32.2M | $31.8M | $493K | +2% |
| Interest & other, net | $1.9M | $1.6M | $293K | +18% |
| Research & development | $3.1M | $3.3M | −$150K | -5% |
| SG&A | $24.3M | $24.3M | $21K | +0.1% |
| Other operating costs | $4.8M | $4.2M | $622K | +15% |
| Operating cash sources | $7.3M | $7.8M | −$520K | -7% |
| Depreciation & amortization | $1.4M | $1.4M | −$10K | -0.7% |
| Share-based compensation | $820K | $1.1M | −$295K | -26% |
| Working capital & other | $3.5M | −$4.9M | $8.4M | — |
| Cash used in operations | $1.6M | $10.2M | −$8.6M | -85% |
| Net loss absorbed | $7.3M | $7.8M | −$520K | -7% |
Questions
How much did Biodesix's revenue grow quarter over quarter in Q2 2026?
Biodesix's revenue rose $1.3M (+5%) from $25.6M in Q1 2026 to $26.9M in Q2 2026.
What drove Biodesix's revenue change in Q2 2026?
Diagnostic Tests +$3.1M (+14%); Development Services −$1.8M (-54%).